Navigation Links
CWRU receives $5 million from Ohio Third Frontier Commission
Date:6/25/2009

CLEVELAND June 25, 2009 The Center for Stem Cell & Regenerative Medicine (CSCRM), comprised of Case Western Reserve University (CWRU), Cleveland Clinic (CC), University Hospitals (UH), and Athersys, Inc. has received $5 million from Ohio's Third Frontier Commission under the Research Commercialization Program. The funding will help support new and innovative stem cell technologies including two commercial, four emerging and three pilot projects. This funding will be matched by each of the projects to create a $10 million grant benefiting stem cell and regenerative medicine in Ohio.

"This funding provides CSCRM the support it needs to continue to aggressively move new technologies from academic labs towards commercial development," said Stan Gerson, Director of the Center for Stem Cell & Regenerative Medicine. "We have linked corporate partners to our major projects and have been gratified by the development of a stem cell biotechnology commercial landscape in our region. Our goal is to rapidly move stem cell research from the lab to patients through clinical trials, using our strong background in preclinical models."

The continued research efforts will result in efficient clinical applications and commercialization of stem cells to benefit patients throughout Ohio. To date, such efforts have brought in $170 million in new commercial development and investment in Ohio.

"This grant continues to build distinctive and broad reach capabilities that are making Ohio a leader in the development and clinical use of cellular therapies," said Baiju R. Shah, President and CEO of BioEnterprise. "Ohioans benefit both through the resulting company development and jobs as well as by having access to leading-edge clinical therapies at our region's clinical institutions."

The use of stem cells has focused on leukemia and myeloma treatments with recent applications in cardiovascular disease. Current healthcare is limited to the use of drugs or devices to treat disease and injury. CSCRM, located in Northeast Ohio but collaborating state wide, is uniquely positioned to rapidly implement new stem cell technologies in the commercial and therapeutic arenas.

"I can see stem cells replacing drugs to improve many diseases," said Dr. Gerson. "Stem cells can replace injured cells, improve the function of many organs in the body and provide specific new functions to treat many diseases."

The Third Frontier funding will support the following commercial, emerging and pilot programs:

Commercial programs

The commercial projects are expected to generate significant near term value for the sponsoring companies and the State of Ohio.

  • Athersys and Kenneth Cooke (UHCMC and CWRU) will further evaluate MultiStem to cure immunological reactions to cell related therapies for cancer. The goal of this project is to advance the commercialization of MultiStem cell therapy by running a FDA approved Phase II clinical trial to evaluate the performance of the cells.

  • Juventas Therapeutics, spin out company from Marc Penn (CC), will develop its lead drug product, stromal cell derived factor 1 (SDF-1), through a Phase I clinical trial for critical limb ischemia.

Emerging programs

With further refinement of already established proof of concept, the following programs could mature into significant opportunities for CSCRM and the region.

  • Dr. Gerson is partnering with Lentigen, Inc, of Gaithersburg, MD to develop a gene therapy approach to treating brain tumors.

  • Jean Welter (CWRU) and Adam Lambert (Oakwood Laboratories) are teaming up to develop a combination product comprised of a drug and Oakwood's proprietary sustained release technology to treat arthritic disease.

  • Eben Alsberg (CWRU) and Orthopediatrics of Warsaw, IN will use microspheres tuned to release a specific amount of drug over a prolonged period of time to tell the patient's cells to create cartilage.

  • Bruce Trapp (CC) and Vertex Pharmaceuticals of Cambridge, MA have identified a cell in the adult human brain and will evaluate its potential to treat a variety of neurodegenerative diseases and spinal cord injury.

Pilot programs

The pilot projects represent early stage, cutting edge scientific projects that were developed in the Center. While these projects are at an early stage, they were selected based upon their significance to the field and their potential economic impact if successfully matured. Funding for the three projects will be accompanied by a subset of eight new pilot projects determined through review by CSCRM oversight committees.

  • Paul Tesar (CWRU), Horst von Recum (CWRU) and Jeremy Rich (CC) will establish a Pluripotent Stem Cell Facility within CWRU and CC which will be the first of its kind in the State of Ohio.

  • Cell Targeting will apply its cell "painting" technology to direct umbilical cord blood stem cells to specific locations in the body to increase cell dosage and improve engraftment.

  • Zhenghong Lee (UHCMC) and Jeremy Rich (CC) will collaborate to develop a method to non-invasively image cancer stem cells through the development of radiolabeled tracers.

The CSCRM Administration, led by Debra Grega and Michael Gilkey, is responsible for coordinating, accounting and reporting on all of these projects, continuing and creating education programs on stem cells and regenerative medicine for middle school through graduate level students, executing a biennial international stem cell conference (MSC 2009), interfacing and cultivating new commercial interactions, developing new research collaborations within the State as well as internationally, and representing the Center in scientific conferences and public events.


'/>"/>

Contact: Christina DeAngelis
cat41@case.edu
216-368-3635
Case Western Reserve University
Source:Eurekalert

Related biology news :

1. Susan E. Gardiner receives ASHS Outstanding International Horticulturist Award
2. McGill University receives almost $63 million under CFI program to support five research projects
3. UNH researcher receives presidential environmental award
4. Jefferson receives $1.7 million grant to study stem cells in intervertebral discs of the spine
5. Tulane receives grant to study limb regeneration
6. Springer Series editor John Smol receives two prestigious biology awards
7. URI receives $18 million grant to strengthen biomedical research capacity in Rhode Island
8. Vitamin D expert receives Linus Pauling Prize for Health Research
9. UC Riverside geneticist receives highest honor from Botanical Society of America
10. WPI professor receives Fulbright Scholarship to work on tissue engineering in Ireland
11. UC Davis bioengineer receives Hartwell Foundation grant to address skull fusion disorder of infants
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/18/2016)... 2016  Extenua Inc., a pioneering developer of ... and access of ubiquitous on-premise and cloud storage, today ... Cyber.  ... C4ISR and Cyber initiatives in support of National ... technology solutions," said Steve Visconti , Extenua ...
(Date:1/11/2016)...  higi, the leading retail and omni-channel community engagement ... and mobile, today announced it has closed funding ... --> --> ... higi,s health platform – its network of health ... expanding services and programs to retail partners and ...
(Date:1/7/2016)... , Jan. 7, 2016  A United States ... the first court in the country to interpret a ... lawsuit to go forward against the photo website Shutterfly ... BRIAN NORBERG vs. SHUTTERFLY, INC.; and ... plaintiff alleges that Shutterfly violates the Illinois Biometric Privacy ...
Breaking Biology News(10 mins):
(Date:2/4/2016)... -- ContraVir Pharmaceuticals, Inc. (NASDAQ: CTRV ), a ... targeted antiviral therapies, announced today that it will present ... held February 8-9, 2016, at the Waldorf Astoria New ... Healthcare Conference, taking place in New York ... Sapirstein , Chief Executive Officer of ContraVir, will provide ...
(Date:2/4/2016)... Brooklyn, NY (PRWEB) , ... February 04, 2016 , ... ... cuvettes for over 10 years. What sets them apart from other cuvette ... that is posted on their website. On top of this steady flow of ...
(Date:2/3/2016)... and HOLLISTON, Mass., Feb. 3, 2016 Harvard ... a biotechnology company developing bioengineered organ implants for ... today announced that CEO Jim McGorry , ... Investor Conference on Tuesday, February 9, 2016 ... York City . HART,s presentation will be ...
(Date:2/3/2016)... , ... February 03, 2016 , ... ... annual report which summarizes and analyzes nearly 750 unique supply chain ... alert, and analysis service. , Supply chain risk management practitioners subscribe to ...
Breaking Biology Technology: